Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
BMC Health Services Research
Published in: BMC Health Services Research 1/2018

Open Access 01-12-2018 | Research article

Trends in healthcare utilization and costs associated with pneumonia in the United States during 2008–2014

Authors: Sabine Tong, Caroline Amand, Alexia Kieffer, Moe H. Kyaw

Published in: BMC Health Services Research | Issue 1/2018

Login to get access

Abstract

Background

Pneumonia is the leading cause of morbidity and mortality worldwide. Pneumococcal conjugate vaccines have reduced the burden of pneumonia, but data on the current burden of pneumonia and its impact on the healthcare system are needed to inform the development and use of new vaccines and other preventive measures.

Methods

We retrospectively analyzed the frequency of pneumonia in the US during 2008–2014 using data from the MarketScan® Commercial Claims and Encounters database. Frequencies of healthcare utilization related to the index pneumonia episode were calculated using the annual number of enrolled person-years (PY) as the denominator and the number of individuals with pneumonia as the numerator. Pneumonia-associated costs were calculated as mean payment per episode during the 2 years from 2013 to 2014.

Results

The overall annual healthcare utilization rate for pneumonia was 15.1 per 1000 PY and decreased slightly from 2008 to 2014 (from 15.4 to 13.5 per 1000 PY). Most pneumonia-related healthcare utilization was due to office/outpatient visits (10.3 per 1000 PY; 68.3%). Emergency department/urgent care visits (2.5 per 1000 PY; 16.9%) and hospitalizations (2.2 per 1000 PY; 14.8%) contributed less. Pneumonia-related healthcare utilization was highest in children < 5 years (rate per 1000 PY = 29.7 for < 1 year, 47.9 for 1 year, and 39.5 for 2–4 years) and adults > 65 years (45.0 per 1000 PY). The mean cost per pneumonia episode (95% confidence interval) was US$429.1 ($424.8–$433.4) for office/outpatient visits, $1126.9 ($1119.5–$1134.3) for emergency department/urgent care visits, and $10,962.5 ($10,822.8–$11,102.2) for hospitalization.

Conclusions

The burden of pneumonia on the US healthcare system remains substantial. The results presented here can help guide new vaccination strategies and other preventive interventions for reducing the remaining burden of pneumonia.
Appendix
Available only for authorised users
Literature
1.
Liu L, Oza S, Hogan D, Perin J, Rudan I, Lawn JE, et al. Global, regional, and national causes of child mortality in 2000–13, with projections to inform post-2015 priorities: an updated systematic analysis. Lancet. 2015;385:430–40.CrossRefPubMed
2.
3.
Simonetti AF, Viasus D, Garcia-Vidal C, Carratala J. Management of community-acquired pneumonia in older adults. Ther Adv Infect Dis. 2014;2:3–16.PubMedPubMedCentral
4.
5.
Marston BJ, Plouffe JF, File TM Jr, Hackman BA, Salstrom SJ, Lipman HB, et al. Incidence of community-acquired pneumonia requiring hospitalization. Results of a population-based active surveillance study in Ohio. The community-based pneumonia incidence study group. Arch Intern Med. 1997;157:1709–18.CrossRefPubMed
6.
Geno KA, Gilbert GL, Song JY, Skovsted IC, Klugman KP, Jones C, et al. Pneumococcal capsules and their types: past, present, and future. Clin Microbiol Rev. 2015;28:871–99.CrossRefPubMedPubMedCentral
7.
8.
Almirall J, Serra-Prat M, Bolibar I, Balasso V. Risk factors for community-acquired pneumonia in adults: a systematic review of observational studies. Respiration. 2017;94:299–311.CrossRefPubMed
9.
File TM Jr, Marrie TJ. Burden of community-acquired pneumonia in north American adults. Postgrad Med. 2010;122:130–41.CrossRefPubMed
10.
Welte T, Torres A, Nathwani D. Clinical and economic burden of community-acquired pneumonia among adults in Europe. Thorax. 2012;67:71–9.CrossRefPubMed
11.
Update: pneumococcal polysaccharide vaccine usage--United States. MMWR Morb Mortal Wkly Rep. 1984;33:273–6 81.
12.
Preventing pneumococcal disease among infants and young children. Recommendations of the advisory committee on immunization practices (ACIP). MMWR Recomm Rep. 2000;49:1–35.
13.
Licensure of a 13-valent pneumococcal conjugate vaccine (PCV13) and recommendations for use among children - Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep. 2010;59:258–61.
14.
Schiffner-Rohe J, Witt A, Hemmerling J, von Eiff C, Leverkus FW. Efficacy of PPV23 in preventing pneumococcal pneumonia in adults at increased risk--a systematic review and meta-analysis. PLoS One. 2016;11:e0146338.CrossRefPubMedPubMedCentral
15.
Shaughnessy EE, Stalets EL, Shah SS. Community-acquired pneumonia in the post 13-valent pneumococcal conjugate vaccine era. Curr Opin Pediatr. 2016;28:786–93.CrossRefPubMed
16.
Tin Tin Htar M, Stuurman AL, Ferreira G, Alicino C, Bollaerts K, Paganino C, et al. Effectiveness of pneumococcal vaccines in preventing pneumonia in adults, a systematic review and meta-analyses of observational studies. PLoS One. 2017;12:e0177985.CrossRefPubMedPubMedCentral
17.
Center IVA. The evidence base for pneumococcal conjugate vaccines (PCVs): data for decision-making around PCV use in childhood. Baltimore (MD): Johns Hopkins University; 2017.
18.
19.
Hansen L. The Truven health MarketScan databases for life sciences researchers. Ann Arbor, MI: Truven Health Analytics; 2017.
20.
Zhou F, Shefer A, Kong Y, Nuorti JP. Trends in acute otitis media-related health care utilization by privately insured young children in the United States, 1997-2004. Pediatrics. 2008;121:253–60.CrossRefPubMed
21.
Said MA, Johnson HL, Nonyane BA, Deloria-Knoll M, O'Brien KL, Andreo F, et al. Estimating the burden of pneumococcal pneumonia among adults: a systematic review and meta-analysis of diagnostic techniques. PLoS One. 2013;8:e60273.CrossRefPubMedPubMedCentral
22.
23.
Hayes BH, Haberling DL, Kennedy JL, Varma JK, Fry AM, Vora NM. Burden of pneumonia-associated hospitalizations: United States, 2001-2014. Chest. 2018;153:427–37.CrossRefPubMed
24.
Griffin MR, Mitchel E, Moore MR, Whitney CG, Grijalva CG. Declines in pneumonia hospitalizations of children aged <2 years associated with the use of pneumococcal conjugate vaccines - Tennessee, 1998-2012. MMWR Morb Mortal Wkly Rep. 2014;63:995–8.PubMedPubMedCentral
25.
Simonsen L, Taylor RJ, Schuck-Paim C, Lustig R, Haber M, Klugman KP. Effect of 13-valent pneumococcal conjugate vaccine on admissions to hospital 2 years after its introduction in the USA: a time series analysis. Lancet Respir Med. 2014;2:387–94.CrossRefPubMed
26.
Park H, Adeyemi AO, Rascati KL. Direct medical costs and utilization of health care services to treat pneumonia in the United States: an analysis of the 2007-2011 medical expenditure panel survey. Clin Ther. 2015;37:1466–76 e1.CrossRefPubMed
27.
de St Maurice A, Grijalva CG, Fonnesbeck C, Schaffner W, Halasa NB. Racial and regional differences in rates of invasive pneumococcal disease. Pediatrics. 2015;136:e1186–94.CrossRefPubMedPubMedCentral
28.
Dirmesropian S, Wood JG, MacIntyre CR, Beutels P, McIntyre P, Menzies R, et al. Cost-effectiveness of 13-valent pneumococcal conjugate vaccine (PCV13) in older Australians. Vaccine. 2017;35:4307–14.CrossRefPubMed
29.
Chen J, O'Brien MA, Yang HK, Grabenstein JD, Dasbach EJ. Cost-effectiveness of pneumococcal vaccines for adults in the United States. Adv Ther. 2014;31:392–409.CrossRefPubMedPubMedCentral
30.
Ament A, Baltussen R, Duru G, Rigaud-Bully C, de Graeve D, Ortqvist A, et al. Cost-effectiveness of pneumococcal vaccination of older people: a study in 5 western European countries. Clin Infect Dis. 2000;31:444–50.CrossRefPubMed
31.
Smith KJ, Wateska AR, Nowalk MP, Raymund M, Nuorti JP, Zimmerman RK. Cost-effectiveness of adult vaccination strategies using pneumococcal conjugate vaccine compared with pneumococcal polysaccharide vaccine. JAMA. 2012;307:804–12.PubMedPubMedCentral
Metadata
Title
Trends in healthcare utilization and costs associated with pneumonia in the United States during 2008–2014
Authors
Sabine Tong
Caroline Amand
Alexia Kieffer
Moe H. Kyaw
Publication date
01-12-2018
Publisher
BioMed Central
Published in
BMC Health Services Research / Issue 1/2018
Electronic ISSN: 1472-6963
DOI
https://doi.org/10.1186/s12913-018-3529-4

Other articles of this Issue 1/2018

BMC Health Services Research 1/2018 Go to the issue

Research article

Adoption and use of guidelines for whiplash: an audit of insurer and health professional practice in New South Wales, Australia

Study protocol

Enhancing system-wide implementation of opioid prescribing guidelines in primary care: protocol for a stepped-wedge quality improvement project

Research article

Elusive implementation: an ethnographic study of intersectoral policymaking for health

Research article

Implementation of district-based clinical specialist teams in South Africa: Analysing a new role in a transforming system

Research article

Applying the consolidated framework for implementation research to identify barriers affecting implementation of an online frailty tool into primary health care: a qualitative study

Research article

Policy environment for prevention, control and management of cardiovascular diseases in primary health care in Kenya